Gemin X Biotechnologies was established in late 1998, in Montréal, Québec as a spin-out of McGill University. The company completed a second round funding in May 2001. Gemin X Biotechnologies seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. The company's mission is to develop integrated capabilities in target discovery and validation, high-throughput screening, medicinal chemistry and preclinical development form the core of the company's discovery engine.